3-deoxyglucosone has been researched along with avapro in 1 studies
| Studies (3-deoxyglucosone) | Trials (3-deoxyglucosone) | Recent Studies (post-2010) (3-deoxyglucosone) | Studies (avapro) | Trials (avapro) | Recent Studies (post-2010) (avapro) |
|---|---|---|---|---|---|
| 186 | 8 | 77 | 1,369 | 385 | 495 |
| Protein | Taxonomy | 3-deoxyglucosone (IC50) | avapro (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.3067 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0099 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanssen, NMJ; Hovind, P; Parving, HH; Persson, F; Piazza, M; Rossing, P; Schalkwijk, CG; Scheijen, JL; Stehouwer, CDA; van de Waarenburg, MPH; van Greevenbroek, MMJ | 1 |
1 trial(s) available for 3-deoxyglucosone and avapro
| Article | Year |
|---|---|
Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chromatography, Liquid; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glyoxal; Humans; Irbesartan; Male; Middle Aged; Pyruvaldehyde; Tandem Mass Spectrometry; Time Factors; Treatment Outcome | 2021 |